Journal article
Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres
M Grant, A Haydon, L Au, S Wilkins, K Oliva, E Segelov, Y Antill, P Carne, P Ranchod, A Polglase, C Farmer, M Chin, R Wale, P Simpson, S Bell, S Skinner, P McMurrick, J Shapiro
International Journal of Surgery | ELSEVIER SCIENCE BV | Published : 2018
Abstract
Background/Objectives: Adjuvant chemotherapy for Stage II colon cancer offers a small (2-3%) overall survival benefit and is not universally recommended. Mismatch repair deficiency (dMMR) confers an improved prognosis identifying patients unlikely to benefit from adjuvant chemotherapy. The aim of this study was to investigate the use of dMMR immunohistochemistry in two major cancer treatment centres. Methods: Prospective data were collected on all patients with resected Stage II colon cancer between 2010 and 2015 across two large Australian hospitals. Data collected included patient demographics, tumour histology, dMMR immunohistochemistry, chemotherapy use, and outcomes. Results: All 355 pa..
View full abstractGrants
Funding Acknowledgements
This study was funded in part by "Let's Beat Bowel Cancer" (www.letsbeatbowelcancer.com.au), a benevolent fund raising and public awareness foundation.